← board
VTGN
VistaGen Therapeutics, Inc.distress 5/10 · elevated risk$0.230%today-95% from 52w high
Psychiatry / CNS 3
Lead: social anxiety disorder
Revenue
pre-revenue
Liquidity
$31M
Runway
0.7 yrs
Shares 1y
+34%
Price & events
-65.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.5%
1D
-4.6%
1W
-63.7%
1M
-59.8%
3M
-64.8%
6M
-91.6%
1Y
-94.2%
2Y
-99.7%
5Y
-99.7%
All
Overview
- Market Cap
- $9.39M
- Volume
- 140.61K
- 52 Week Range
- $0.23 – $4.90
- Total Shares
- 41.03M
- Float Shares
- 35.04M
- Short %
- 3.89%
- % Held by Insiders
- 0.29%
- % Held by Institutions
- 40.77%
- RVOL
- 0.04x
- Beta
- 0.40
Pipeline stages · 1 programs
Fasedienol Nasal Spray
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-04-21 | Phase 3 | Fasedienol Nasal Sprayfast track | Social Anxiety Disorder (SAD) | 238 | active not recruiting |
| 2026-04 | Phase 2 | Fasedienol Nasal Spray - Fasedienol Nasal Sprayfast track | Social Anxiety Disorder | 60 | recruiting |
| 2025-10-31 | Phase 3 | Fasedienol Nasal Sprayfast track | Social Anxiety Disorder | 238 | active not recruiting |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 5
- third quarter of 2026Guided 70%readoutPhase 2fasedienol · Topline results from Phase 2 Repeat Dose studySEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- first half of 2026readoutPhase 2fasedienol · Topline results for Phase 2 repeat dose study of fasedienol for SAD.SEC 8-K
- 2026-04-22fda agreementrefisolone · FDA issued Study May Proceed letter under IND for refisolone nasal spray for moderate to severe vasomotor symptoms due to menopause, enabling Phase 2 development in the US.SEC 8-K
- by year endreadoutPhase 3fasedienol · Topline results for PALISADE-3 trialSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $1 (+337% upside) · 2 analysts
- 2025-12-17William BlairOutperform → Market Perform
- 2025-12-17Maxim GroupBuy → Hold
- 2025-12-17JefferiesBuy → Hold
Competitors — social anxiety disorder
Recent news
- 2026-07-18VTGN News | VISTAGEN THERAPEUTICS INC (NASDAQ:VTGN) - ChartMill
- 2026-07-15Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results? - Yahoo Finance
- 2026-07-15VTGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
- 2026-07-12VTGN Stockholders Have Opportunity to Lead Vistagen Therapeutics - The National Law Review
- 2026-07-08VistaGen Therapeutics (VTGN) TD Cowen 45th Annual Health Care Conference Summary - Quartr
- 2026-07-03Price to sales forward of Vistagen Therapeutics, Inc. – NASDAQ:VTGN - TradingView
- 2026-07-02Form 4 VistaGen Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
- 2026-07-02ESPP grant gives Vistagen (NASDAQ: VTGN) CFO 11,712 new shares - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.